Changes in Hong Kong stocks | Kangfang Biotech (09926) rose more than 3%, and the first-line treatment of gastric cancer with cardonil was approved by the FDA

The Zhitong Finance App learned that Kang Fang Biotech (09926) rose by more than 3%. As of press release, it had risen 3.83% to HK$121.9, with a turnover of HK$271 million.

According to news, according to Kang Fang Biotech's official Weibo, the company recently announced that the world's first multi-center phase III clinical study (COMPASSION-37/AK104-311) has been approved by the US Food and Drug Administration (FDA) for the first-line treatment of HER2-negative, unresectable or metastatic gastric or gastroesophageal adenocarcinoma compared with chemotherapy combined with or without navulimab.

According to reports, the COMPASSION-37 study is Cardonelli's second international multi-center registered clinical study. Previously, an internationally registered clinical study of the cardonil regimen to treat immune-resistant hepatocellular carcinoma has already been conducted in the US. The development of the COMPASSION-37 study is another critical step forward in the global development of Cardonilli. It is also an important step in Health Biotech's global strategy, and will strongly reinforce the company's leading international position in the field of cancer immunization 2.0.